Instil Bio, Inc.
TIL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TIL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TIL
Instil Bio, Inc. is a clinical-stage biotechnology company focused on acquiring and developing novel product candidates, currently advancing ITIL-306 in a Phase 1 trial and managing a lean cash position with substantial doubt about its ability to continue as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Instil Bio, Inc..
Instil Bio, Inc. is a clinical-stage biotechnology company focused on acquiring and developing novel product candidates, currently advancing ITIL-306 in a Phase 1 trial and managing a lean cash position with substantial doubt about its ability to continue as a going concern.
- Instil Bio is a public biotech company focused on acquiring and developing product candidates, with no approved products and a terminated Phase 1 trial for ITIL-306 [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported cash and equivalents of $5.8M, net loss of -$4.3M, and shareholders' equity of $113.9M [sec].
- The company has substantial doubt about its ability to continue as a going concern, as conditions may not be alleviated [sec_mda · as of 2026-08-13].
- Instil Bio is selling its Tarzana facility to preserve cash, with the facility listed for sale as of March 2025 [sec_mda · as of 2025-11-13].
- The company's future operating expenses depend on factors such as in-licensing, clinical trial costs, regulatory timelines, and manufacturing expenses [sec_mda · as of 2026-08-13].
What works
- Instil Bio has a strategic focus on business development and in-licensing, which could allow it to acquire promising product candidates without heavy internal R&D costs [sec_mda · as of 2026-08-13].
- The company maintains a lean cash position with $5.8M in cash as of June 30, 2026, and is actively managing expenses through asset sales like the Tarzana facility [sec_mda · as of 2025-11-13].
- Instil Bio has a public company structure and access to capital markets, which may support future funding if needed [sec_mda · as of 2026-08-13].
What to weigh
- The company has substantial doubt about its ability to continue as a going concern, with conditions that may not be alleviated [sec_mda · as of 2026-08-13].
- Instil Bio's only clinical program, ITIL-306, was terminated in a Phase 1 trial, leaving no active clinical-stage pipeline [catalyst].
- The company has no approved products and faces significant uncertainty in estimating future funding requirements due to risks in acquiring and developing product candidates [sec_mda · as of 2026-08-13].
- Cash and equivalents of $5.8M as of June 30, 2026, are limited, and the company may need to raise additional capital to sustain operations beyond near-term [sec].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern
“within Complex Therapeutics LLC's control, alleviate the conditions that raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · August 13, 2026
ITIL-306 trial terminated
“Status: Terminated.”
Catalysts · August 24, 2022
Sale of Tarzana facility
“In March 2025, the Board of Directors approved a plan to sell the Tarzana facility and we listed our Tarzana facility for sale.”
SEC MD&A · November 13, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern, with conditions not fully within company's control [sec_mda · as of 2026-08-13].
- No active clinical pipeline — Only clinical program (ITIL-306) terminated, leaving no product candidates in active development [catalyst].
- Limited cash runway — Cash and equivalents of $5.8M as of June 30, 2026, may not sustain operations without additional funding [sec].
- Dependence on business development — Future success relies on acquiring or in-licensing product candidates, which is uncertain and costly [sec_mda · as of 2026-08-13].
What to watch
- Progress on sale of Tarzana facility and impact on cash runway [sec_mda · as of 2025-11-13].
- Any new business development or in-licensing agreements to rebuild pipeline [sec_mda · as of 2026-08-13].
- Ability to raise additional capital through equity or debt offerings [sec_mda · as of 2026-08-13].
- Regulatory or clinical updates on any future product candidates [sec_mda · as of 2026-08-13].
Sources: Catalysts · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Instil Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Instil Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
16.5 months
D/E 0.84 · 0% dilution
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$11.0M
| Holder | Shares | Value |
|---|---|---|
| cpmg inc | 410,922 | $3.4M |
| vanguard capital management llc | 349,166 | $2.9M |
| millennium management llc | 132,946 | $1.1M |
| renaissance technologies llc | 59,100 | $487K |
| blackrock, inc. | 52,018 | $429K |
| nomura asset management international inc. | 50,000 | $412K |
| geode capital management, llc | 49,011 | $404K |
| citadel advisors llc | 38,562 | $318K |
| lpl financial llc | 32,063 | $264K |
| xtx topco ltd | 26,242 | $216K |
Showing top 10 of 28 institutional holders of Instil Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 10.3%
- Days to cover
- 15.6
- Shares short
- 414,920
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TIL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Instil Bio, Inc.?
Instil Bio, Inc. is a clinical-stage biotechnology company focused on acquiring and developing novel product candidates, currently advancing ITIL-306 in a Phase 1 trial and managing a lean cash position with substantial doubt about its ability to continue as a going concern.
What is Instil Bio, Inc.'s lead drug candidate?
Instil Bio, Inc.'s most advanced tracked candidate is axn-2510/imm2510 (Phase 1) for Solid Tumor, Adult.
Who is the CEO of Instil Bio, Inc.?
Mr. Bronson Crouch is the chief executive officer of Instil Bio, Inc. (TIL).
Where is Instil Bio, Inc. headquartered?
Instil Bio, Inc. (TIL) is headquartered in Dallas, TX, United States.
What therapeutic areas does Instil Bio, Inc. focus on?
Instil Bio, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.